Ethacizine

Chemical compound
  • C01BC09 (WHO)
Legal statusLegal status
  • Prescription only (RU)
Pharmacokinetic dataBioavailability~40% (oral)[1]Protein binding90%MetabolismExtensive hepaticElimination half-life2.5 hoursIdentifiers
  • ethyl N-[10-[3-(diethylamino)propanoyl]phenothiazin-2-yl]carbamate
CAS Number
  • 33414-33-4 checkY
PubChem CID
  • 107841
ChemSpider
  • 96982 checkY
UNII
  • FE5SPV1Z6G
KEGG
  • D10503 checkY
ChEMBL
  • ChEMBL1997663 ☒N
CompTox Dashboard (EPA)
  • DTXSID50187057 Edit this at Wikidata
Chemical and physical dataFormulaC22H27N3O3SMolar mass413.54 g·mol−13D model (JSmol)
  • Interactive image
  • CCN(CC)CCC(=O)N1C2=CC=CC=C2SC3=C1C=C(C=C3)NC(=O)OCC
  • InChI=1S/C22H27N3O3S/c1-4-24(5-2)14-13-21(26)25-17-9-7-8-10-19(17)29-20-12-11-16(15-18(20)25)23-22(27)28-6-3/h7-12,15H,4-6,13-14H2,1-3H3,(H,23,27) checkY
  • Key:PQXGNJKJMFUPPM-UHFFFAOYSA-N checkY

Ethacizine (ethacyzine) is a class Ic antiarrhythmic agent, related to moracizine.[2] It is used in Russia and some other CIS countries for the treatment of severe and/or refractory ventricular and supraventricular arrhythmias, especially those accompanied by organic heart disease. It is also indicated as a treatment of refractory tachycardia associated with Wolff–Parkinson–White syndrome.[1]

It is manufactured under the brand name Ethacizin (Этацизин) by Latvian pharmaceutical company Olainfarm.[3]

Synthesis

For the treatment of heart infarction:[4][5]

Synthesis:[6] Patent:[7]

The amide formation between Phenothiazine-2-ethylcarbamate [37711-29-8] (1) and 3-Chloropropionyl chloride [625-36-5] (2) gives ethyl N-[10-(3-chloropropanoyl)phenothiazin-2-yl]carbamate [119407-03-3] [34749-22-9] (3). Displacement of the remaining ω-halogen by diethylamine (4) then completes the synthesis of ethacizine (5).

References

  1. ^ a b "Этацизин (Ethacyzin) Prescribing Information. VIDAL Drug Compendium" (in Russian). Retrieved 5 February 2014.
  2. ^ Kaverina NV, Sokolov SF (April 1992). "Pharmacology and clinical use of a new group of antiarrhythmic drugs: derivatives of tricyclic nitrogen-containing systems". Pharmacological Research. 25 (3): 217–25. doi:10.1016/s1043-6618(05)80070-2. PMID 1518765.
  3. ^ "Этацизин—4DOKTOR.RU Drug Information Handbook" (in Russian). Retrieved 5 February 2014.
  4. ^ E I Chazov, et al. SE 8302120  (1984).
  5. ^ E I Chazov, FR 2544985  (to 1985 to INST FARMAKOLOGII AKADEMII M).
  6. ^ Gritsenko, A. N.; Skoldinov, A. P. (1986). "Ethacizine and its metabolites". Pharmaceutical Chemistry Journal. 20 (4): 279–282. doi:10.1007/BF00758818.
  7. ^ Evgeny Ivanovich Chazov, et al. GB 2139211  (1984 to NII FARMAKOL AKAD MED).
  • v
  • t
  • e
Channel blockers
class I
(Na+ channel blockers)
class Ia (Phase 0→ and Phase 3→)
class Ib (Phase 3←)
class Ic (Phase 0→)
class III
(Phase 3→, K+ channel blockers)
class IV
(Phase 4→, Ca2+ channel blockers)
Receptor agonists
and antagonists
class II
(Phase 4→, β blockers)
A1 agonist
M2
α receptors
Ion transporters
Na+/ K+-ATPase
Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e